Table 2.
Factors Associated With Receipt of HCV Testing Using GEE Model (Binary Outcome)
| Factor | AOR (95% CI) |
|---|---|
|
| |
| Year (2013–2018)a | 1.06 (1.05, 1.07) |
| Raceb | |
| White versus Black | 0.85 (0.83, 0.87) |
| Asian versus Black | 0.92 (0.91, 0.93) |
| Othersc versus Black | 1.08 (1.07, 1.10) |
| Hispanic versus Non-Hispanic | 0.98 (0.96, 1.00) |
| Male versus femaleb | 0.73 (0.71, 0.75) |
| Age (ref: 51–64 years)b | |
| 18–35 | 0.98 (0.95, 1.01) |
| 36–50 | 0.99 (0.97, 1.00) |
| Clinical conditionsd | |
| Pregnancy | 0.97 (0.92, 1.02) |
| HIV | 2.11 (1.96, 2.28) |
| Cirrhosis | 1.71 (1.51, 1.95) |
| Hepatitis B virus | 1.57 (1.23, 1.99) |
| Smoking | 1.06 (1.03, 1.09) |
| Type of SUD (ref: other substances alone)b | |
| Alcohol alone | 1.02 (1.01, 1.03) |
| Opioid alone | 1.04 (1.02, 1.06) |
| Opioid + alcohol | 1.06 (1.03, 1.09) |
| Other substances + alcohol | 1.08 (1.04, 1.12) |
| Other substances + opioid | 1.10 (1.05, 1.15) |
| Other substances + opioid+ alcohol | 1.12 (1.06, 1.18) |
| Behaviorsd | |
| Receipt of blood transfusion | 1.31 (1.22, 1.40) |
| Receipt of HIV test | 2.09 (2.00, 2.18) |
| Receipt of syringe with sterile needle | 2.09 (2.00, 2.18) |
| Receipt of psychotherapy | 1.16 (1.11, 1.21) |
| SUD treatmentb | 1.14 (1.07, 1.21) |
The authors used 2013–2018 data to establish the new SUD cohort, whereas the 2012 data were used to ensure at least 1 year of continuous enrollment prior to the first SUD diagnosis or receiving initial treatment for SUD.
Race, sex, age, type of SUD and SUD treatment were measured at the index date when patients were newly diagnosed with SUD.
Other races include American Indian or Alaska Native, Native Hawaiian or other Pacific islander, or multiple races, or people who refused to answer, or unknown race.
Clinical conditions and patient behaviors were measured 1 year before the index date when patients were newly diagnosed with SUD.
HCV, hepatitis C virus; SUD, substance use disorders; GEE, generalized estimating equation.